In 2022, innovative Chinese medicines will usher in more opportunities!

With the continuous release of favorable national policies, innovative traditional Chinese medicine drugs have also achieved rapid development as part of the traditional Chinese medicine industry
.
In 2021, under the promotion of the reform of the Chinese medicine review and approval system, the number of approved Chinese medicine innovative drugs will reach 11, a new high in the past five years
.
In 2022, two more innovative traditional Chinese medicine drugs have been approved for marketing, namely Huzhen Qingfeng Capsules from Yili Pharmaceutical and Jieyu Chufan Capsules from Yiling Pharmaceuticals
.
In addition, the research and development speed of innovative Chinese medicine drugs is also increasing.
According to the data of clinical projects in the past three years, the proportion of clinical applications for innovative Chinese medicine drugs in 2021 will reach 65%, which is twice that of 2020
.
The industry generally believes that there will be more opportunities for innovative traditional Chinese medicine drugs in 2022
.
On the one hand, the policy wind has arrived, and innovative traditional Chinese medicine drugs will set sail
.
For example, in December 2021, the "Guiding Opinions on Medical Insurance Supporting the Inheritance, Innovation and Development of Traditional Chinese Medicine" pointed out that it is necessary to give full play to the advantages of medical insurance to support the innovation, inheritance and development of traditional Chinese medicine, and include qualified traditional Chinese medicine medical institutions into the scope of fixed-point settlement in different places to expand traditional Chinese medicine.
The radiation capacity of medical institutions, and formulate payment policies that conform to the laws of traditional Chinese medicine
.
Among them, in the new version of drug registration classification Jianhua traditional Chinese medicine registration classification, traditional Chinese medicine innovative drugs have become a separate category, which shows the support for traditional Chinese medicine innovative drugs in terms of policy
.
After the above-mentioned new policies were released, many securities institutions expressed their optimism about the development of traditional Chinese medicine
.
For example, Ping An Securities stated in the research report that the document further demonstrated the state's high recognition of traditional Chinese medicine and strengthened its support for the development of the traditional Chinese medicine industry
.
The issuance of the document will promote the further release of the demand for traditional Chinese medicine, thereby benefiting the long-term development of the industry
.
Great Wall Securities also released a research report, arguing that a number of national policy dividends continue to promote the inheritance, innovation and development of the traditional Chinese medicine and health industry, the strategic position of traditional Chinese medicine has been continuously improved, and the traditional Chinese medicine industry has ushered in development opportunities.

.
In addition, on January 15, the State Administration of Traditional Chinese Medicine issued the "Development Plan for Promoting the High-quality Integration of Traditional Chinese Medicine into the Belt and Road Initiative (2021-2025)", which clarified the development goals during the "14th Five-Year Plan" period, including cooperation with the Build 30 high-quality Chinese medicine overseas centers, promulgate 30 international standards for Chinese medicine, build 10 overseas Chinese medicine culture brand projects, build 50 Chinese medicine international cooperation bases and a batch of national Chinese medicine Serving export bases, strengthening the construction of overseas registration service platforms for traditional Chinese medicine products,
etc.
Brokerages believe that, on the whole, the traditional Chinese medicine industry may become a good sector for the scarcity of pharmaceutical products in 2022
.
On the other hand, under the trend of medical insurance cost control, compared with western medicine innovative drugs, traditional Chinese medicine innovative drugs are less affected by the medical insurance cost control policy
.
In recent years, the number of proprietary Chinese medicines included in medical insurance has been increasing, and a total of 8 innovative Chinese medicines listed on the market from 2017 to 2021 have entered the medical insurance catalog
.
The overall negotiation pass rate of traditional Chinese medicine is also relatively high.
In 2017, 2019, and 2021, the negotiation pass rates were 62.
5%, 95.
8%, and 83.
9%, respectively.
Among them, in the medical insurance negotiation in 2021, the number of traditional Chinese medicine products that won the bid far exceeds that of western medicine
.
In addition, from the perspective of the decline in medical insurance negotiations, the decline in traditional Chinese medicine is relatively mild, and the price pressure is less
.
In addition, some people in the industry also pointed out that in terms of payment method reform, according to the "Inheritance Opinions on Traditional Chinese Medicine" issued by the Medical Insurance Bureau on December 30, 2021, traditional Chinese medicine medical institutions may temporarily not implement DRG payment, and for areas that have implemented DRG/DIP, Appropriately increase the coefficient and score of TCM medical institutions and TCM diseases
.
It is understood that DRG payment is a medical insurance cost control management tool, which divides patients into different diagnosis groups according to different conditions for packaged treatment and payment
.
Under this payment model, most pharmaceutical companies are faced with uncertainty, but only traditional Chinese medicine stands out
.